Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus CEFOTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus CEFOTAN.
CECLOR CD vs CEFOTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
1-2 g IV/IM every 12 hours for 5-10 days; up to 6 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
Terminal elimination half-life: 4.5 hours (intravenous). In patients with renal impairment (CrCl <30 mL/min), half-life extends to approximately 20–30 hours, requiring dose adjustment.
Renal: ~80% unchanged; biliary/fecal: ~20%
Primarily renal (unchanged); ~88% excreted in urine within 24 hours. Biliary/fecal elimination is negligible (<1% as metabolites).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic